You are here

AusPAR: Omalizumab

Australian Public Assessment Report

6 May 2021
AusPAR Details
AusPAR
Active Ingredient
Omalizumab
Product Name
Xolair
Sponsor
Novartis Pharmaceuticals Australia Pty Ltd
Submission Number
PM-2019-05980-1-5
Submission Type
Extension of indication
Decision
Approved
AusPAR Date
15 April 2021
Publication Date

6 May 2021